Clinical trials: Ophthalmic Solutions
Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
- Trial name
- NCT04735393
- Testing
- Reproxalap Ophthalmic Solution (0.25%)
- Where
- United States
- Volunteers
- 757 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
- Trial name
- NCT07568730
- Testing
- Lacripep, Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- TearSolutions, Inc.
Open-angle Glaucoma, Ocular Hypertension
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00637130
- Testing
- Travoprost ophthalmic solution, 0.0008%, Travoprost ophthalmic solution, 0.001%, Travoprost ophthalmic solution, 0.0012%
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT02057575
- Testing
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Where
- 23 sites in United States
- Volunteers
- 298 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye
A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days…
- Trial name
- NCT02975102
- Testing
- CBL-101 Eye Drops, Vismed® Multi Eye Drops
- Where
- 2 sites in Belgium, France
- Volunteers
- 87 people
- Sponsor
- Laboratoire Chauvin
Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome
Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy
The main aim of this investigation is to evaluate the effect of the preservative-free ophthalmic solution IRIDIUM® A gel on the ocular surface of patients with glaucoma or OHT and concomitant DES under multiple long-term topical…
- Conditions
- Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome, Ocular Hypertension and Concomitant Dry Eye Syndrome, Multiple Long-term Topical Hypotensive Therapy
- Trial name
- NCT06190028
- Testing
- Iridium A Gel
- Where
- 3 sites in Italy
- Volunteers
- 65 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Dry Eye Disease, Ocular Surface Disease
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
This is a phase I study evaluating safety and tolerability of PRO-229 ophthalmic solution through he incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), incidence of chemosis, and changes in…
- Trial name
- NCT06370585
- Testing
- PRO-229, Lagricel® Ofteno PF
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Corneal Epithelial Defect
To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis
An investigator-initiated single-center, randomized, double-blind, placebo-controlled clinical study .The main purpose is to evaluate the effectiveness of ZKY001 eye drops in treating corneal epithelial defects caused by…
- Trial name
- NCT07120308
- Testing
- ZKY001 eye drops
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Dry Eye Syndrome
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
- Trial name
- NCT03982368
- Testing
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 261 people
- Sponsor
- Dompé Farmaceutici S.p.A
Contact Lens Related Dry Eye
Clinical Evaluation of the Causes of Contact Lens Related Dry Eye
The purpose of this study was to clinically evaluate the potential causes of contact lens-related dry eye.
- Trial name
- NCT00995189
- Testing
- Opti-Free RepleniSH, ReNu MultiPlus, Contact lenses
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
The purpose of this study is to compare Systane® ULTRA lubricant eye drops to OPTIVE® lubricating eye drops for ocular surface staining within dry eye subjects and to evaluate the safety of Systane® ULTRA after 3 months of use.
- Trial name
- NCT01863368
- Testing
- Preservative-free saline solution eyedrops, Systane® ULTRA lubricant eyedrops, OPTIVE® lubricating eyedrops
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Healthy
Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers
Instillation of artificial tears is standard treatment in dry eye syndrome and in patients experiencing dry eye symptoms when wearing contact lenses.
- Trial name
- NCT00135824
- Testing
- Povidone K25 eye drops (povidone)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to TRAVATAN® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.
- Trial name
- NCT01493427
- Testing
- Travoprost 0.004%
- Volunteers
- 202 people
- Sponsor
- Alcon Research
Allergic Rhinoconjunctivitis
Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops.
- Trial name
- NCT02131051
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Bitop AG
Keratitis, Corneal Ulcer
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of refractory corneal…
- Trial name
- NCT05255016
- Testing
- PXL Platinum 330 system + Riboflavin 0.25% TE Solution
- Where
- 12 sites in United States
- Volunteers
- 488 people
- Sponsor
- Peschke GmbH
Glaucoma, Ocular Hypertension
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
The study purpose is to evaluate the safety of T4090.
- Trial name
- NCT05389267
- Testing
- Kinezodianone R hydrochloride
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Laboratoires Thea
Diabetic Macular Edema, Age-related Macular Degeneration
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a…
- Trial name
- SPIOC-101 (NCT02314299)
- Testing
- MTP-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stealth BioTherapeutics Inc.
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Myopia, Astigmatism
Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems
The purpose of this study is to evaluate the lipid uptake, wetting characteristics, and visual performance of AIR OPTIX® AQUA and ACUVUE® OASYS® with HYDRACLEAR® contact lenses when used in conjunction with two contact lens care…
- Conditions
- Myopia, Astigmatism, Refractive Error
- Trial name
- NCT01699750
- Testing
- Lotrafilcon B contact lenses, Senofilcon A contact lenses, OPTI-FREE® PUREMOIST® MPDS
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Alcon Research
Presbyopia
Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hydrochloride (HCl) ophthalmic solution (AGN-190584) when administered bilaterally, once daily for 30 days in participants with presbyopia.
- Trial name
- GEMINI 1 (NCT03804268)
- Testing
- Vehicle, Pilocarpine HCl Ophthalmic Solution
- Where
- 36 sites in United States
- Volunteers
- 323 people
- Sponsor
- Allergan